News
The day at a glance · 3 min read
Mood · Cautious
+15
Sentiment, −100 to +100
ISRG Share Price
$412.18
MedTech & Surgical Robotics
3-Year Return
43.1%
MedTech & Surgical Robotics
CAR T Market 2026
$7.24B
Cell & Gene Therapy Markets
Key driverClinical data presentations from AbbVie across multiple therapeutic areas and positive Phase 3 obesity trial results from Eli Lilly
Daily briefHealthcare· Money365.Market AI ·

AbbVie Pipeline Data, Lilly Obesity Trial Lead Healthcare

Multiple AbbVie readouts at EASD and EADV conferences highlight dermatology and metabolic franchises; Lilly retatrutide delivers weight loss in Phase 3

Big Pharma & Biotech Pipeline

Bullish
ABBVLLYBMY
AbbVie (ABBV) announced detailed Phase 1 results for ABBV-295, an investigational long-acting amylin analog, in a presentation at the European Association for the Study of Diabetes 2026 Annual Meeting in Milan, evaluating tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous ABBV-295 in adults through a multiple ascending dose study. The company also presented primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study evaluating zumilokibart in adult patients with moderate to severe atopic dermatitis as a late-breaker at the EADV Congress in Vienna.
AbbVie (ABBV) showcased new research across its dermatology portfolio with 60 abstracts at EADV 2026, including three late-breaking presentations reflecting the company's expanding portfolio across immune-mediated skin diseases with investigational compounds lutikizumab and zumilokibart alongside approved therapies.
Eli Lilly (LLY) announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating retatrutide, a first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with type 2 diabetes and obesity or overweight. At 80 weeks, all doses of retatrutide delivered substantial weight loss and reductions in A1C, with the company making Zepbound (tirzepatide) and Foundayo (orforglipron) as existing marketed products.
Bristol Myers Squibb (BMY) reported first-time pivotal Phase 3 EXCALIBER-RRMM data in September 2026 showing ZENBEXUS (iberdomide) plus daratumumab and dexamethasone produced a statistically significant, clinically meaningful improvement in minimal residual disease–negative complete responses versus a standard daratumumab-based regimen in relapsed or refractory multiple myeloma. The MRD-focused outcome informs the accelerated approval pathway for ZENBEXUS in this indication.

MedTech & Surgical Robotics

Neutral
ISRG
Intuitive Surgical (ISRG) has delivered a 43.1% gain over the past three years, though the stock has been weaker more recently, with the current share price at $412.18 now drawing focus on whether that valuation is properly backed by the cash the business can generate. Instruments and Accessories alone generate roughly 60% of the company's revenue on a per-procedure basis, creating a tight link between surgery volume and cash flow that explains why investors reacted sharply when Intuitive noted in its fiscal Q2 2026 call that U.S. procedure growth had slowed.

Cell & Gene Therapy Markets

Bullish

CAR T Market 2031 Forecast

$13.78B+13.7% CAGR
BMYJNJ
The global CAR T-cell therapy market is projected to grow from $7.24 billion in 2026 to $13.78 billion by 2031, registering a 13.7% CAGR according to market research released September 30. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers, with Yescarta leading the product market in 2025 and hospitals representing the largest end-user segment. Key players in the market include Bristol-Myers Squibb (BMY), Gilead Sciences, Novartis, and Johnson & Johnson (JNJ).

FDA & Clinical Development

Bullish
JNJ
Johnson & Johnson (JNJ) reported new long-term IMAAVY data in generalized myasthenia gravis, including adolescent outcomes, with adolescents with gMG on IMAAVY showing sustained disease control and reduced reliance on corticosteroids with no new safety signals. Survey findings from healthcare professionals indicated IMAAVY may address unmet needs for more consistent symptom management in gMG treatment.

Healthcare M&A and Corporate Moves

Neutral
MRKUNH
Merck (MRK) stock slipped 1.5% following announcement of a $400 million agreement to acquire KRAS rights, with the deal potentially reaching $2.13 billion in total value, though the asset remains a preclinical cancer candidate.
UnitedHealth Group (UNH) is getting a new head of its insurance division, with executive Robert Hunter disclosing on September 28 that he will take the role in a LinkedIn post, though the firm has issued no comments on the reasoning behind the leadership change.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy